[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Caspase 3 - Pipeline Review, H2 2019

December 2019 | 76 pages | ID: C13308D19E02EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Caspase 3 - Pipeline Review, H2 2019

SUMMARY

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Caspase-3 is a caspase protein encoded by the CASP3 gene. It interacts with caspase-8 and caspase-9. It cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. It cleaves and activates caspase-6, -7 and -9. It is involved in the cleavage of huntingtin. It triggers cell adhesion in sympathetic neurons through RET cleavage.

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) pipeline Target constitutes close to 10 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III and Preclinical stages are 1 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Cardiovascular, Central Nervous System, Hematological Disorders, Infectious Disease, Metabolic Disorders, Ophthalmology and Toxicology which include indications Glomerulonephritis, Inflammatory Bowel Disease, Age Related Macular Degeneration, Alzheimer's Disease, Bladder Cancer, Chemotherapy Induced Neutropenia, Colorectal Cancer, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myocardial Infarction, Non-Small Cell Lung Cancer, Parkinson's Disease, Prostate Cancer, Small-Cell Lung Cancer, Solid Tumor, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Zika Virus Infections.

The latest report Caspase 3 - Pipeline Review, H2 2019, outlays comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)
  • The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Overview
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Companies Involved in Therapeutics Development
BeyondSpring Inc
Clayton Biotechnologies Inc
Marine Biomedical Research Institute of Qingdao
New World Laboratories Inc
Takeda Pharmaceutical Co Ltd
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Drug Profiles
BaxB-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BaxG-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flavokawain A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBRI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NWL-283 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plinabulin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Caspase-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Procaspase-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Dormant Products
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Discontinued Products
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Product Development Milestones
Featured News & Press Releases
Dec 19, 2019: BeyondSpring publishes report on benefits and mechanism of Plinabulin in reducing neutropenia with multiple chemotherapies
Dec 10, 2019: BeyondSpring’s study 106 phase 3 superior trial design combining plinabulin with pegfilgrastim versus pegfilgrastim alone for chemotherapy-induced neutropenia presented at ASH 2019 Annual Meeting
Dec 09, 2019: BeyondSpring’s abstracts on clinical evidence for bone marrow stem cell protection as plinabulin’s mechanism of action for CIN accepted at American Society of Hematology’s 2019 Annual Meeting
Nov 11, 2019: BeyondSpring’s single-blinded design of phase 3 study 103 (DUBLIN-3) prevented premature patient drop-out: Data Accepted for Presentation at SITC 2019
Oct 23, 2019: BeyondSpring enrolls first patient in global phase 3 clinical trial with Plinabulin in combination with G-CSFto prevent chemotherapy-induced neutropenia
Oct 17, 2019: BeyondSpring’s Lead Asset, Plinabulin, granted U.S. patent covering methods of treating brain tumors
Oct 08, 2019: Cell journals publishes BeyondSpring’s announces prenew data on mechanism of plinabulin to mature dendritic cells, leading to t-cell activation
Oct 01, 2019: BeyondSpring presents novel trial design for DUBLIN-3 study BPI-2358-103 at ESMO Congress 2019
Sep 23, 2019: BeyondSpring’s Plinabulin continues to build on superior product profile in breast cancer trial for neutropenia prevention
Sep 10, 2019: BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC Presented at 2019 IASLC World Conference on Lung Cancer
Aug 23, 2019: BeyondSpring plinabulin demonstrates superior quality of life over pegfilgrastim in a head-to-head comparison trial for the prevention of neutropenia
May 20, 2019: BeyondSpring abstract demonstrating bone pain benefit with lead asset, Plinabulin, versus Neulasta for neutropenia prevention Presented at ISPOR 2019
May 16, 2019: BeyondSpring's rationale for the plinabulin-neulasta combination for neutropenia prevention accepted as abstracts at 2019 ASCO Annual Meeting
Mar 26, 2019: BeyondSpring's lead asset, Plinabulin, shifts the balance of macrophages towards anti-cancer M1s
Mar 25, 2019: BeyondSpring advancing patient targeting strategies for lead asset Plinabulin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by BeyondSpring Inc, H2 2019
Pipeline by Clayton Biotechnologies Inc, H2 2019
Pipeline by Marine Biomedical Research Institute of Qingdao, H2 2019
Pipeline by New World Laboratories Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

BeyondSpring Inc
Clayton Biotechnologies Inc
Marine Biomedical Research Institute of Qingdao
New World Laboratories Inc
Takeda Pharmaceutical Co Ltd


More Publications